Analysts have recently updated their ratings and price targets for Merck & Co (NYSE:MRK), showing a diverse range of opinions but generally positive sentiment. The average 12-month price target has been raised to $134.88, indicating a 3.66% increase from the previous target. The company's financial performance shows a positive revenue trend with a growth rate of 5.78% as of December 31, 2023, but it faces challenges in net margin, ROE, and ROA, which are below industry averages. Merck's strong market presence and substantial size are highlighted by its market capitalization and sound financial structure, as evidenced by a low debt-to-equity ratio.